...

Case Challenge

Treatment of a Genotype 1a Patient Not Achieving Full Virologic Suppression With Peginterferon/Ribavirin at 24 Weeks

Source: New Options for HCV Nonresponders: Navigating Emerging Data and Best Practices for Treatment-Experienced Patients

Treatment of a Genotype 1a Patient Not Achieving Full Virologic Suppression With Peginterferon/Ribavirin at 24 Weeks


Faculty:

Maria H. Sjogren, MD, MPH, FACP
  • Maria H. Sjogren, MD, MPH, FACP

CREDIT INFORMATION

Release Date: 06/13/08

Expiration Date: 06/12/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 0.8 Nursing contact hours

Physician Assistants: maximum of 1.0 hour of AAPA Category I (Preapproved) credit

Status: Please log in to view status

Begin the Case Challenge

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the types of responses an HCV-infected patient might achieve with standard peginterferon/ribavirin therapy
  • Summarize the treatment options for partial responders to peginterferon/ribavirin
  • Discuss the effects of baseline factors on future treatment strategies for nonresponders and partial responders

Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.